½ÃÀ庸°í¼­
»óǰÄÚµå
1447087

ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç° À¯Çüº°, °Ë»ç À¯Çüº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®

Cholesterol Test Market Forecasts to 2030 - Global Analysis By Product Type, Test Type, Distribution Channel, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀåÀº 2023³â 68¾ï 4,000¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È 10.3%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 135¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÄÝ·¹½ºÅ×·Ñ °Ë»ç´Â Ç÷¾× ³» ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡¸¦ ÃøÁ¤ÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÏ´Â Áø´Ü ÀýÂ÷ÀÔ´Ï´Ù. Àú¹Ðµµ Áö´Ü¹é(LDL), °í¹Ðµµ Áö´Ü¹é(HDL), Áß¼ºÁö¹æÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Á¾·ùÀÇ ÄÝ·¹½ºÅ×·ÑÀ» Æò°¡ÇÏ°í ½ÉÇ÷°ü °Ç°­ »óŸ¦ Æò°¡ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î ÄÝ·¹½ºÅ×·Ñ °Ë»ç´Â Ç÷¾×À» äÃëÇÏ¿© ½Ç½ÃÇϸç, ½ÉÀ庴ÀÌ ¹ß»ýÇϰųª ½ÉÇ÷°ü ÁúȯÀÌ ¹ß»ýÇÒ À§ÇèÀÌ ÀÖ´Â »ç¶÷À» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2022³â¿¡´Â 6¾ï 5,000¸¸ ¸í ÀÌ»óÀÇ ¼ºÀÎÀÌ ºñ¸¸ÀÔ´Ï´Ù.

½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡

½ÉÀ帶ºñ¿Í ³úÁ¹ÁßÀ» Æ÷ÇÔÇÑ ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ³ôÀº ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡´Â ÀÌ·¯ÇÑ ÁúȯÀÇ ÁÖ¿ä À§Çè ¿ä¼ÒÀÔ´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·üÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÄÝ·¹½ºÅ×·Ñ °Ë»çÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÄÝ·¹½ºÅ×·Ñ °Ë»ç´Â Àú¹Ðµµ Áö´Ü¹é(LDL) ÄÝ·¹½ºÅ×·Ñ, °í¹Ðµµ Áö´Ü¹é(HDL) ÄÝ·¹½ºÅ×·Ñ, Áß¼ºÁö¹æ µî ´Ù¾çÇÑ ÄÝ·¹½ºÅ×·Ñ ¼ººÐÀÇ ¼öÄ¡¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Àü¹ÝÀûÀ¸·Î ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

³ôÀº ºñ¿ë

°Ë»ç½Ç °Ë»ç, Áø´Ü Àåºñ, Àü¹®°¡ ºñ¿ë µî ÄÝ·¹½ºÅ×·Ñ °Ë»ç¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀº ƯÈ÷ º¸Çè¿¡ °¡ÀÔÇÏÁö ¾Ê¾Ò°Å³ª ÀÇ·á ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ ¼ö ¾ø´Â »ç¶÷µé¿¡°Ô °æÁ¦Àû À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â Àú·ÅÇÑ °Ë»ç ¿É¼ÇÀ» Á¦°øÇØ¾ß ÇÏ´Â Çʿ伺°ú ¼öÀͼºÀ» À¯ÁöÇÏ°í ¿î¿µ ºñ¿ëÀ» Ãæ´çÇÏ´Â °Í »çÀÌ¿¡¼­ ±ÕÇüÀ» ¸ÂÃç¾ß ÇÏ´Â °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±× °á°ú, ³ôÀº ºñ¿ëÀº ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå¿¡ Å« À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀü

»õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¿Í ¸ÖƼÇ÷º½º °Ë»ç Ç÷§ÆûÀÇ ÅëÇÕÀ¸·Î Á¾ÇÕÀûÀÎ ÁöÁú ÇÁ·ÎÆÄÀϸµÀÌ °¡´ÉÇØÁ® ±âÁ¸ÀÇ ÄÝ·¹½ºÅ×·Ñ ÃøÁ¤¿¡ ±×Ä¡Áö ¾Ê°í ½ÉÇ÷°ü À§Çè ¿äÀÎÀ» º¸´Ù Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ½ÇÇè½Ç ±â¹Ý ÄÝ·¹½ºÅ×·Ñ °Ë»ç ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÚµ¿ ºÐ¼®±â ¹× °í󸮷® ½Ã½ºÅÛÀ» µµÀÔÇÏ¿© °Ë»ç È¿À²¼º°ú È®À强À» Çâ»ó½Ã۰í ÀÎÀû ¿À·ù ¹× ¿î¿µ ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

Á¦ÇÑÀûÀÎ ÀνÄ

¸¹Àº »ç¶÷µéÀÌ ÄÝ·¹½ºÅ×·Ñ °Ë»ç°¡ ½ÉÀ庴°ú ³úÁ¹Áß À§ÇèÀ» Æò°¡ÇÏ´Â µ¥ ÀÖ¾î Áß¿äÇÏ´Ù´Â »ç½ÇÀ» ¸ð¸£°í ÀÖÀ¸¸ç, ƯÈ÷ ¹«Áõ»óÀÚÀÇ °Ë»ç ºñÀ²ÀÌ ³·½À´Ï´Ù. ¶ÇÇÑ, ÄÝ·¹½ºÅ×·Ñ °Ë»ç ÀýÂ÷¿¡ ´ëÇÑ ¿ÀÇØ¿Í À߸øµÈ Á¤º¸, ħ½À¼º¿¡ ´ëÇÑ ÀνÄ, äÇ÷¿¡ µû¸¥ ºÒÆíÇÔ µîÀÌ °Ë»ç¸¦ ¹ÞÁö ¾ÊÀ¸·Á´Â »ç¶÷µéÀ» ´õ ¸Ö¸®ÇÏ°Ô ¸¸µé ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ³·Àº ÀÎÁöµµ´Â ½ÃÀå È®´ë¸¦ Á¦ÇÑÇÏ´Â Å« ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19´Â ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Ãʱ⿡´Â ÀÇ·á ½Ã½ºÅÛÀÇ ÃÊÁ¡ÀÌ À§±â °ü¸®¿¡ ÁýÁߵǾî ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¹× ¿¹¹æ ÀǷḦ Æ÷ÇÔÇÑ ÀÏ»óÀûÀÎ ÀÇ·á ¼­ºñ½ºÀÇ Áß´ÜÀ¸·Î À̾îÁ³½À´Ï´Ù. ±ÞÇÏÁö ¾ÊÀº ¸¹Àº ÀÇ·á ¿¹¾àÀÌ ¿¬±âµÇ°Å³ª Ãë¼ÒµÇ¾î ÄÝ·¹½ºÅ×·Ñ °Ë»ç°¡ °¨¼ÒÇß½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ·¯½º °¨¿°¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ²À ÇÊ¿äÇÑ °æ¿ì¸¦ Á¦¿ÜÇϰí´Â ÀÇ·á ½Ã¼³À» ÇÇÇÏ°Ô µÇ¸é¼­ ÄÝ·¹½ºÅ×·Ñ °Ë»ç¸¦ ¹Þ´Â »ç¶÷ÀÇ ¼ö°¡ ´õ¿í °¨¼ÒÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Å×½ºÆ® ŰƮ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»ó

°Ë»ç ŰƮ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ Å°Æ®¿¡´Â ÀϹÝÀûÀ¸·Î ±âÁ¸ ½ÇÇè½Ç ÀÌ¿ÜÀÇ Àå¼Ò¿¡¼­ ÄÝ·¹½ºÅ×·Ñ °Ë»ç¸¦ ¼öÇàÇÏ´Â µ¥ ÇÊ¿äÇÑ ¸ðµç ±¸¼º¿ä¼Ò°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. Á¾Á¾ °Ë»ç ½ºÆ®¸³, äÇ÷¿ë ·£½Ë, ºÐ¼®¿¡ ÇÊ¿äÇÑ ¿ë¾× ¹× ½Ã¾àÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â ¶ÇÇÑ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ŰƮ¸¦ »ç¿ëÇÏ¿© ȯÀÚ Áø·á ¹× °Ç°­ °ËÁø ½Ã ½Å¼ÓÇÑ Æò°¡¸¦ ¼öÇàÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Å°Æ®´Â ºü¸¥ °á°ú¸¦ Á¦°øÇÏ¿© Àû½Ã¿¡ °³ÀÔ ¹× Ä¡·á °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ÃÑ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»ó

ÃÑ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ °Ë»ç´Â °í¹Ðµµ Áö´Ü¹é(HDL) ÄÝ·¹½ºÅ׷Ѱú Àú¹Ðµµ Áö´Ü¹é(LDL) ÄÝ·¹½ºÅ×·Ñ, ±×¸®°í Áß¼ºÁö¹æÀ» Æ÷ÇÔÇÑ Ç÷Áß ÄÝ·¹½ºÅ×·ÑÀÇ ÃÑ·®À» ÃøÁ¤ÇÕ´Ï´Ù. ÃÑ ÄÝ·¹½ºÅ×·Ñ °Ë»ç´Â ¿¹¹æÀû °Ç°­ °ü¸®¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, °³ÀÎÀÇ ÁöÁú ÇÁ·ÎÇʰú Àü¹ÝÀûÀÎ ½ÉÇ÷°ü °Ç°­ »óÅ¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

ºÏ¹Ì Áö¿ªÀº źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ÷´Ü Áø´Ü ±â¼ú, ½ÉÇ÷°ü Áúȯ À§ÇèÀÎÀÚÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â Çõ½ÅÀûÀÎ ÄÝ·¹½ºÅ×·Ñ ÀúÇÏÁ¦ ¹× Áø´Ü ±â¼úÀ» °³¹ßÇÏ´Â Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀÌ ´Ù¼ö Á¸ÀçÇÏ¿© ½ÃÀå ¼ºÀå°ú ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °øÁߺ¸°Ç Ä·ÆäÀΰú ±³À° Ȱµ¿À¸·Î ÀÎÇØ ÄÝ·¹½ºÅ×·Ñ °ü¸®¿Í °Ç°­ÇÑ »ýȰ½À°ü ¼±ÅÃÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¼­ºñ½º ¹× Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È ¼öÀͼº ³ôÀº ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡µéÀº °í·ÉÈ­¿Í °¡Ã³ºÐ ¼ÒµæÀÌ ³ôÀº Áß»êÃþÀÇ Áõ°¡¿Í °°Àº Àα¸ Åë°èÇÐÀû º¯È­¸¦ °æÇèÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÄÝ·¹½ºÅ×·Ñ °Ë»ç¸¦ Æ÷ÇÔÇÑ ÇコÄÉ¾î ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÉÇ÷°ü°è °Ç°­ ÁõÁø ¹× Áúº´ ¿¹¹æ ÇÁ·Î±×·¥ µî ºñ°¨¿°¼º Áúȯ¿¡ ´ëóÇϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·ÂÀº ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ Á¦°ø:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù:

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®(ÃÖ´ë 3°³»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤Ä¡, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º °ËÅä¿¡ µû¸¥)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù¹ý
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • °¡Á¤

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå : Á¦Ç° À¯Çüº°

  • °Ë»ç ½ºÆ®¸³
  • °Ë»ç ŰƮ
  • °Ë»ç ¹ÌÅÍ
  • ±âŸ Á¦Ç° À¯Çü

Á¦6Àå ¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°

  • °í¹Ðµµ ¸®Æ÷´Ü¹éÁú(HDL) ÄÝ·¹½ºÅ×·Ñ
  • Àú¹Ðµµ ¸®Æ÷´Ü¹éÁú(LDL) ÄÝ·¹½ºÅ×·Ñ
  • ÃÑ ÄÝ·¹½ºÅ×·Ñ °Ë»ç
  • Áß¼º Áö¹æ/VLDL ÄÝ·¹½ºÅ×·Ñ °Ë»ç
  • ±âŸ °Ë»ç À¯Çü

Á¦7Àå ¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå : À¯Åë ä³Îº°

  • ÀϹÝÀǾàǰ(OTC)
  • ó¹æÀü ±â¹Ý

Á¦8Àå ¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ÀçÅà Äɾî
  • º´¿ø°ú Ŭ¸®´Ð
  • Áø´Ü ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ¼¼°èÀÇ ÄÝ·¹½ºÅ×·Ñ °Ë»ç ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦11Àå ±â¾÷ °³¿ä

  • Thermo Fisher Scientific
  • Cell Biolabs, Inc.
  • Randox Laboratories Ltd.
  • Clinical Reference Laboratory, Inc.
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • Alere Inc.
  • PTS Diagnostics
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • Horiba Ltd
  • Danaher Corp
  • Abbott Laboratories
  • Nova Biomedical
ksm 24.04.24

According to Stratistics MRC, the Global Cholesterol Test Market is accounted for $6.84 billion in 2023 and is expected to reach $13.5 billion by 2030 growing at a CAGR of 10.3% during the forecast period. A cholesterol test is a diagnostic procedure aimed at measuring the levels of cholesterol in the blood. It assesses various types of cholesterol, including low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, which are essential for evaluating cardiovascular health. Typically conducted through a blood sample, cholesterol testing helps identify individuals at risk of developing heart disease or experiencing cardiovascular events.

According to the World Health Organization (WHO), in 2022, over 650 million adults were obese.

Market Dynamics:

Driver:

Rising prevalence of cardiovascular diseases

Cardiovascular diseases, including heart attacks and strokes, are leading causes of morbidity and mortality globally. High cholesterol levels are a major risk factor for these diseases. As the prevalence of cardiovascular diseases continues to rise, there is a growing need for cholesterol testing. Cholesterol testing helps in assessing the levels of different cholesterol components, such as low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Overall, the rising prevalence of cardiovascular diseases is a factor driving market demand.

Restraint:

High cost

The high costs associated with cholesterol testing procedures, including laboratory tests, diagnostic equipment, and professional fees, can create financial barriers for individuals, particularly those without adequate insurance coverage or access to healthcare services. Moreover, healthcare providers face challenges in balancing the need to provide affordable testing options with maintaining profitability and covering operational expenses. As a result, high costs present a significant threat to the cholesterol test market.

Opportunity:

Technological advancements

The integration of novel biomarkers and multiplex testing platforms enables comprehensive lipid profiling, providing a more holistic assessment of cardiovascular risk factors beyond traditional cholesterol measurements. Furthermore, advancements in laboratory-based cholesterol testing technologies have led to the introduction of automated analyzers and high-throughput systems, enhancing testing efficiency and scalability while reducing human error and operational costs.

Threat:

Limited awareness

Many individuals remain unaware of the importance of cholesterol testing in assessing their risk of heart disease and stroke, leading to low testing rates, especially among asymptomatic individuals. Additionally, misconceptions or misinformation about cholesterol testing procedures, perceived invasiveness, or discomfort associated with blood draws may further deter individuals from seeking testing. Therefore, limited awareness is a significant factor limiting market expansion.

Covid-19 Impact

The COVID-19 pandemic had a negative impact on the cholesterol test market. Initially, the focus of healthcare systems shifted towards managing the crisis, leading to disruptions in routine medical services, including cholesterol testing and preventive care. Many non-urgent medical appointments were postponed or cancelled, resulting in a decline in cholesterol screenings. Additionally, concerns about virus transmission prompted individuals to avoid healthcare facilities unless absolutely necessary, further reducing the number of people seeking cholesterol tests.

The test kits segment is expected to be the largest during the forecast period

The test kits segment is estimated to hold the largest share. These kits typically contain all the necessary components for conducting cholesterol tests outside of traditional laboratory settings. They often include test strips, lancets for blood sampling, and solutions or reagents required for analysis. Healthcare providers also rely on cholesterol test kits for rapid assessments during patient consultations or health screenings. Additionally, these kits offer quick results, allowing for timely interventions and treatment decisions.

The total cholesterol test segment is expected to have the highest CAGR during the forecast period

The total cholesterol test segment is anticipated to have lucrative growth during the forecast period. This test measures the total amount of cholesterol present in the blood, including both high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol, along with triglycerides. The total cholesterol test plays a critical role in preventive healthcare, providing valuable insights into an individual's lipid profile and overall cardiovascular health status.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to the robust healthcare infrastructure, advanced diagnostic technologies, and a high prevalence of cardiovascular disease risk factors. The region is home to numerous pharmaceutical and biotechnology companies engaged in developing innovative cholesterol-lowering medications and diagnostic technologies, driving market growth and innovation. Additionally, public health campaigns and educational efforts raise awareness about the importance of cholesterol management and healthy lifestyle choices, further driving demand for cholesterol testing services and products.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. Countries in the Asia Pacific region are experiencing demographic shifts, including aging populations and the emergence of a middle-class segment with greater disposable income, driving demand for healthcare services, including cholesterol testing. Additionally, government initiatives aimed at addressing non-communicable diseases, including cardiovascular health promotion and disease prevention programs, further propel market growth in this region.

Key players in the market

Some of the key players in the Cholesterol Test Market include Thermo Fisher Scientific, Cell Biolabs, Inc., Randox Laboratories Ltd., Clinical Reference Laboratory, Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Alere Inc., PTS Diagnostics, Eurofins Scientific, F. Hoffmann-La Roche AG, Horiba Ltd, Danaher Corp, Abbott Laboratories and Nova Biomedical.

Key Developments:

In December 2023, Randox Laboratories Ltd and Transgene entered into a scientific collaboration, with the aim of joining their competences to deliver a novel therapeutic approach to oncology therapies.

In May 2023, Thermo Fisher, the world leader in serving science, has signed a Memorandum of Understanding ("MOU") with the National Research and Innovation Agency of Indonesia (BRIN, Badan Riset dan Inovasi Nasional) to enable and enhance the country's national research and innovation infrastructure and capability.

In February 2023, Roche announced that it has expanded its collaboration with Janssen Biotech Inc. (Janssen) to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

In November 2022, Danaher Corporation, a global science and technology innovator, announced that it has entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation.

Product Types Covered:

  • Test Strips
  • Test Kits
  • Test Meters
  • Other Product Types

Test Types Covered:

  • High-Density Lipoprotein (HDL) Cholesterol
  • Low-Density Lipoprotein (LDL) Cholesterol
  • Total Cholesterol Test
  • Triglycerides/VLDL Cholesterol Test
  • Other Test Types

Distribution Channels Covered:

  • Over the Counter
  • Prescription Based

End Users Covered:

  • Homecare
  • Hospitals & Clinics
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cholesterol Test Market, By Product Type

  • 5.1 Introduction
  • 5.2 Test Strips
  • 5.3 Test Kits
  • 5.4 Test Meters
  • 5.5 Other Product Types

6 Global Cholesterol Test Market, By Test Type

  • 6.1 Introduction
  • 6.2 High-Density Lipoprotein (HDL) Cholesterol
  • 6.3 Low-Density Lipoprotein (LDL) Cholesterol
  • 6.4 Total Cholesterol Test
  • 6.5 Triglycerides/VLDL Cholesterol Test
  • 6.6 Other Test Types

7 Global Cholesterol Test Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Over the Counter
  • 7.3 Prescription Based

8 Global Cholesterol Test Market, By End User

  • 8.1 Introduction
  • 8.2 Homecare
  • 8.3 Hospitals & Clinics
  • 8.4 Diagnostic Centers
  • 8.5 Other End Users

9 Global Cholesterol Test Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Thermo Fisher Scientific
  • 11.2 Cell Biolabs, Inc.
  • 11.3 Randox Laboratories Ltd.
  • 11.4 Clinical Reference Laboratory, Inc.
  • 11.5 Quest Diagnostics Incorporated
  • 11.6 Laboratory Corporation of America Holdings
  • 11.7 Alere Inc.
  • 11.8 PTS Diagnostics
  • 11.9 Eurofins Scientific
  • 11.10 F. Hoffmann-La Roche AG
  • 11.11 Horiba Ltd
  • 11.12 Danaher Corp
  • 11.13 Abbott Laboratories
  • 11.14 Nova Biomedical
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦